Simultaneous separation of antihyperlipidemic drugs by green ultrahigh-performance liquid chromatography–diode array detector method: Improving the health of liquid chromatography

Statins in combination with fibrates show beneficial effects on the lipoprotein profile of patients because they have positive complimentary effects on lipid profile. A new green ultrahigh-performance liquid chromatography–diode array detector method for simultaneous analysis of simvastatin (SMV) and fenofibrate (FNF) in standard form, marketed formulations, and self-emulsifying drug delivery system formulations was developed and validated in the present investigation. The method utilized C₁₈ as stationary phase and a combination of methanol:water (8:2) as an eluent. It was found that selected eluent provided short run time (2.5 minutes), better peak symmetry and satisfactory values of other chromatographic parameters such as resolution (Rs = 2.325), capacity factor (k, 3.0 and 4.2 for SMV and FNF, respectively), selectivity (α =1.4), and number of theoretical plates (N, 4265 and 5285 for SMV and FNF, respectively). An excellent linear relationship (r² 0.998 and 0.997 for SMV and FNF, respectively) was observed for linear regression data for the calibration plots. The developed system was validated for accuracy, precision, robustness (˃ 2% for both drugs) and recovery (98–102% for both drugs). Results obtained from the statistical treatment of the values obtained for different parameters proved that the method is suitable, reproducible, and selective for the simultaneous analysis of SMV and FNF in bulk, marketed, and self-emulsifying drug delivery system formulations. The replacement of commonly applied toxic solvents with innocuous and environmentally benign solvents provides a better option than the more toxic processes in drug analysis.     

Beagle犬血浆中辛伐他汀的LC-MS测定

建立了LC-MS法测定Beagle犬血浆中的辛伐他汀。采用C_(18)柱,流动相为乙腈-0.1%甲酸溶液(60:40),以洛伐他汀为内标,采用电喷雾离子化法(ESI)采集正离子,单离子方式检测m/z 419(辛伐他汀)和m/z 405(洛伐他汀)。辛伐他汀在0.5～160ng/ml浓度范围内线性良好,检测限为0.25ng/ml。血浆样品的日内、日间RSD均小于7.7%,方法回收率为92.2%～99.2%,提取回收率为92.8%～100.9%。     

高效液相色谱法测定生长抑素含量及有关物质

目的建立高效液相色谱测定生长抑素含量的方法。方法采用Ominispher C18柱(250 mm×4.6 mm,5μm),流动相A:0.1%TFA水溶液,流动相B:0.1%TFA乙腈溶液,采用梯度洗脱,检测波长:215 nm,流速1.0 mL.min-1。结果方法的线性范围为40~140μg.mL-1。r=0.999 9,平均回收率100.3%,最低检测限为1 ng。结论采用HPLC梯度洗脱法测定生长抑素的含量,分离度好,方法简便,适用于生长抑素的含量测定。     

HPLC法测定比格犬血浆中的辛伐他汀及辛伐他汀羟基酸

目的:建立血浆中辛伐他汀及其主要代谢活性成分辛伐他汀羟基酸的含量测定方法。方法:以洛伐他汀为内标物质,流动相采用甲醇-水-冰醋酸(74:26:0.5),检测波长为238nm,流速为1.0mL·min~(-1)。血浆样品采用乙腈沉淀蛋白处理。并测定了10只比格犬单剂量口服辛伐他汀自乳化胶囊和市售片后的血药浓度。结果:血浆中内源性物质对辛伐他汀及辛伐他汀羟基酸的测定无干扰;最低检出限辛伐他汀为0.5ng·mL~(-1),辛伐他汀羟基酸为0.75ng·mL~(-1);辛伐他汀羟基酸在2～100ng·mL~(-1)浓度范围内线性关系良好,r=0.9989,辛伐他汀在1～50ng·mL~(-1)浓度范围内线性关系良好,r=0.9993;绝对回收率为79.68%～95.3%,方法回收率为89.1%～95.3%;日内精密度 RSD≤2.9%、日间精密度 RSD≤4.6%。结论:本方法处理简单,无干扰,灵敏度高,适合测定生物样本中的辛伐他汀及辛伐他汀羟基酸。     

辛伐他汀微乳的制备及犬体内药物动力学

以辛伐他汀在各种表面活性剂和油中的溶解度及不同体系的最大载油量为指标，筛选微乳处方。用伪三元相图确定微乳区，并以辛伐他汀片为参比制剂，考察辛伐他汀微乳在犬体内的相对生物利用度。结果表明，以Cremophor EL为表面活性剂，Labrafac CC-Lauroglycol 90（6：4，w／w）混合油为油相制得的辛伐他汀微乳粒径为（45．1±6．4）nm，ζ电位为（-17．7±4．3）mV，相对生物利用度为193％。     

辛伐他汀渗透泵型控释片的含量测定

目的建立用高效液相色谱法（HPIC法）测定辛伐他汀渗透泵型控释片含量的方法。方法以十八烷基硅烷键合硅胶为固定相，以乙腈-pH值为4．5的0．0025mol／L磷酸二氢钠溶液（65：35）为流动相，流速为1mL／min，检测波长为238nm。结果辛伐他汀溶液的质量浓度在18．0～60．0μg／mL范围内与峰面积线性关系良好，回收率与精密度均良好。结论HPLC法可准确测定辛伐他汀渗透泵型控释片的含量。     

液相色谱-串联质谱法测定辛伐他汀片的人体药动学和生物等效性

目的:建立人血浆中辛伐他汀浓度的液相色谱-串联质谱(LC-MS／MS)测定法,研究健康受试者单剂量口服辛伐他汀受试或参比制剂后的药动学和生物等效性。方法:20名健康男性受试者进行随机双交叉试验,分别单剂量口服20 mg辛伐他汀受试制剂和参比制剂,采用LC-MS／MS以洛伐他汀为内标正离子选择性反应检测测定辛伐他汀血浆浓度,计算两者的药动学参数及相对生物利用度。结果:受试制剂和参比制剂的血药浓度水平一致,主要药动学参数如下:c_(max)分别为(8．0±s 1．9)和(8．1±1．8)μg·L~(-1);t_(max)分别为(1．9±0．3)和(1．9±0．3)h;t_(1/2)分别为(3．7±1．4)和(4．1±2．2)h;AUC_(0～24)分别为(30±8)和(30±6)μg·h·L~(-1);AUC`(0～∞)分别为(30±8)和(31±7)μg·h·L~(-1)。由2种制剂的AUC_(0～24)计算,受试制剂的相对生物利用度为(101±20)%。结论:建立的LC-MS／MS测定法专属、准确、灵敏度适宜。测得辛伐他汀受试制剂和参比制剂生物等效。     

辛伐他汀自乳化胶囊的体内外评价

目的研究辛伐他汀自乳化胶囊的自乳化能力及在Beagle犬体内的药动学.方法以总体液平衡反向透析法考察自乳化胶囊与市售片的体外释药过程;通过测定不同时间的粒子的散射光强度来评价自乳化速度,光学显微镜下考察乳化后形成的乳滴的大小和分布;采用HPLC法测定Beagle犬血浆药物浓度,并与市售片比较考察自乳化胶囊的体内药动学.结果溶出度结果显示辛伐他汀自乳化胶囊比市售片溶出快、浓度高.辛伐他汀自乳化胶囊在10 min内已基本乳化完全,光学显微镜下检视,乳化后乳滴粒子大多数在2μm以下.药动学测定结果表明与市售片比较,自乳化胶囊血药浓度达峰时间提前[Tmax(1.62±0.15)vs(2.65±0.42)h,P＜0.05],最高血药浓度增大[Cmax(44.28±6.29)vs(12.43±2.51)ng·mL-1,P＜0.05],相对生物利用度为市售片剂的216.8%.结论自乳化胶囊可以显著提高辛伐他汀的体外溶出和体内吸收.     

Pharmacogenetics of response to simvastatin in Chinese patients with hyperlipidaemia

Objective To examine the relationship of single-nucleotide polymorphisms(SNPs)in candidate genes with the lipid responses to simvastatin.Methods Chinese patients were treated with simvastatin 40 mg daily for at least 6 weeks.20 SNPs in 11 genes were genotyped.Results 95 patients age(mean±SD)57.5±10.6 years completed the treatment.The Adiponectin 45T>G polymorphism was significantly related to absolute reductions in total cholesterol(TC)and LDL-cholesterol with a trend(P=0.053)for percentage reductions in TC(TT∶TG∶GG=-38.4%∶-35.6%∶-32.6%).Similar findings were seen with LDL-Receptor(LDLR)SNPs(2052T>C and 1866C>T)with absolute reductions in TC and LDL-cholesterol significantly associated.The Breast Cancer Resistance Protein(ABCG2)421C>A polymorphism was related(P<0.05)to HDL-cholesterol response(CC∶CA∶AA=+0.50%∶-5.73%∶-11.41%).Conclusions Adiponectin,LDLR and ABCG2 SNPs had some influence on the lipid responses to simvastatin.